These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 1273544)

  • 21. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide.
    Walubo A; Chan K; Woo J; Chan HS; Wong CL
    Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):551-6. PubMed ID: 1956210
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Activity of rifampicin administered daily and intermittently on experimental tuberculosis in mice].
    Grosset J; Truffot-Pernot C; Lecoeur H; Guelpa-Lauras CC
    Pathol Biol (Paris); 1983 May; 31(5):446-50. PubMed ID: 6353339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rifampicin mono-resistant Mycobacterium tuberculosis in Bujumbura, Burundi: results of a drug resistance survey.
    Sanders M; Van Deun A; Ntakirutimana D; Masabo JP; Rukundo J; Rigouts L; Fissette K; Portaelst F
    Int J Tuberc Lung Dis; 2006 Feb; 10(2):178-83. PubMed ID: 16499257
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapeutic possibilities of inhalation of rifampicin with dimexide in phthisiopulmonology].
    Gorbach IN; Samtsov VS
    Probl Tuberk; 1991; (3):34-6. PubMed ID: 1871090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparative study on the pharmacokinetics of rifampicin between the old and middle-aged tuberculosis patients].
    Weng FH
    Zhonghua Jie He He Hu Xi Za Zhi; 1990 Oct; 13(5):292-4, 319. PubMed ID: 2085859
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum concentration of isoniazid following administration of the drug alone and in combination with rifampicin in patients of pulmonary tuberculosis.
    Singhal KC; Rathi R; Kishore K; Varshney SC; Varshney DP
    Indian J Physiol Pharmacol; 1986; 30(1):115-7. PubMed ID: 3818028
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pharmacokinetics of intravenous rifampicin (RMP) and its clinical evaluation in purulent bacterial meningitis].
    Di Nola F; Eandi M; Soranzo ML; Capra E; Bosio G; Bramato C; Salassa B; Bendiscioli L
    Minerva Med; 1981 Apr; 72(14):875-92. PubMed ID: 7219797
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon.
    Kuaban C; Bercion R; Koulla-Shiro S
    East Afr Med J; 1997 Aug; 74(8):474-7. PubMed ID: 9487410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ambulatory intermittent rifampicin and ethambutol in the retreatment of pulmonary tuberculosis.
    Sriyabhaya N; Jittinandana A; Kecharanantana P
    J Med Assoc Thai; 1974 Nov; 57(11):551-7. PubMed ID: 4452812
    [No Abstract]   [Full Text] [Related]  

  • 30. [Results of a shortened (6 months) schedule of treatment of pulmonary tuberculosis using INH, RMP and PZA].
    Szymański A; Czaplińska-Jóźwiak E
    Pneumonol Pol; 1987 Jun; 55(6):241-5. PubMed ID: 3317292
    [No Abstract]   [Full Text] [Related]  

  • 31. Fibrinogen and antithrombin III blood levels fluctuations during isoniazid or isoniazid plus rifampicin administration.
    Farmakis M; Travlou O; Aroni S; Fertakis A
    Arzneimittelforschung; 1992 Aug; 42(8):1041-4. PubMed ID: 1418078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Tuberculosis in compromised hosts].
    Kekkaku; 2003 Nov; 78(11):717-22. PubMed ID: 14672050
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Comparative evaluation of rifampicin and isoniazid penetration into the pathological foci of the lungs in tuberculosis patients].
    Kislitsyna NA
    Probl Tuberk; 1985; (4):55-7. PubMed ID: 4001111
    [No Abstract]   [Full Text] [Related]  

  • 34. Serious side effects of rifampin on the course of WHO/MDT: a case report.
    Namisato M; Ogawa H
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):277-82. PubMed ID: 11221090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifampin in original treatment of pulmonary tuberculosis. A United States Public Health Service cooperative therapy trial.
    Corpe R
    Bull Int Union Tuberc; 1972 Feb; 47():41-7. PubMed ID: 4562017
    [No Abstract]   [Full Text] [Related]  

  • 36. [Immunological aspects of adverse reactions during treatment with rifampicin].
    Zeană C; Bănică D; Algeorge G
    Rev Ig Bacteriol Virusol Parazitol Epidemiol Pneumoftiziol Pneumoftiziol; 1981; 30(1):33-7. PubMed ID: 6264568
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Early results of treatment of patients with chronic pulmonary tuberculosis with rifampicin].
    Böszörmenyi M
    Gruzlica; 1974 May; 42(5):407-10. PubMed ID: 4464228
    [No Abstract]   [Full Text] [Related]  

  • 39. [Clinical pharmacology in optimization of therapy of lung diseases].
    Iwainsky H; Wiesner B; Winsel K
    Z Erkr Atmungsorgane; 1991; 177(1-2):40-9. PubMed ID: 1808851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A controlled comparison of daily and intermittent administration of rifampicin in retreatment of pulmonary tuberculosis].
    Yamamoto K; Aizawa H; Sasaoka M; Kawamori Y; Kakuno J
    Kekkaku; 1972 Dec; 47(12):467-73. PubMed ID: 4652425
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.